Dupixent — Cigna
Bullous Pemphigoid
Reauthorization criteria
- Patient has already received at least 6 months of therapy with Dupixent; AND
- Patient has experienced a beneficial clinical response, defined by ONE of the following (a, b, c, d, or e):
- a) Decreased area of skin involvement; OR
- b) Decreased lesions, including blisters or erosions (bullae); OR
- c) Decreased urticaria; OR
- d) Decreased erythema; OR
- e) Reduced or no need for systemic or topical corticosteroid therapy.
Approval duration
1 year